...
tvtx-img

Travere Therapeutics Inc, Common Stock

TVTX

NMQ

$17.15

-$0.03

(-0.17%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.50B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.44M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.70
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$5.12 L
$20.33 H
$17.15

About Travere Therapeutics Inc, Common Stock

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameTVTXSectorS&P500
1-Week Return-2%-0.94%-2.6%
1-Month Return-5.67%-5.08%-1.08%
3-Month Return18.19%-10.62%3.45%
6-Month Return120.15%-6.18%8.57%
1-Year Return81.87%1.98%24.3%
3-Year Return-44.98%-0.93%25.58%
5-Year Return14.64%33.84%84.07%
10-Year Return34.72%102.52%185.12%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue175.34M198.32M227.49M212.02M145.24M[{"date":"2019-12-31","value":77.08,"profit":true},{"date":"2020-12-31","value":87.18,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":93.2,"profit":true},{"date":"2023-12-31","value":63.84,"profit":true}]
Cost of Revenue5.23M6.13M6.78M7.59M11.45M[{"date":"2019-12-31","value":45.71,"profit":true},{"date":"2020-12-31","value":53.5,"profit":true},{"date":"2021-12-31","value":59.25,"profit":true},{"date":"2022-12-31","value":66.31,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit170.10M192.19M220.71M204.43M133.79M[{"date":"2019-12-31","value":77.07,"profit":true},{"date":"2020-12-31","value":87.08,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":92.62,"profit":true},{"date":"2023-12-31","value":60.62,"profit":true}]
Gross Margin97.01%96.91%97.02%96.42%92.12%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":99.89,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.38,"profit":true},{"date":"2023-12-31","value":94.95,"profit":true}]
Operating Expenses269.91M267.57M360.21M455.99M521.93M[{"date":"2019-12-31","value":51.71,"profit":true},{"date":"2020-12-31","value":51.27,"profit":true},{"date":"2021-12-31","value":69.02,"profit":true},{"date":"2022-12-31","value":87.37,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(99.81M)(75.38M)(139.50M)(251.56M)(376.74M)[{"date":"2019-12-31","value":-9981000000,"profit":false},{"date":"2020-12-31","value":-7537700000,"profit":false},{"date":"2021-12-31","value":-13950500000,"profit":false},{"date":"2022-12-31","value":-25156000000,"profit":false},{"date":"2023-12-31","value":-37674400000,"profit":false}]
Total Non-Operating Income/Expense(55.41M)(127.46M)1.59M(16.34M)11.07M[{"date":"2019-12-31","value":-500.64,"profit":false},{"date":"2020-12-31","value":-1151.61,"profit":false},{"date":"2021-12-31","value":14.41,"profit":true},{"date":"2022-12-31","value":-147.64,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(146.45M)(188.79M)(179.68M)(278.17M)(376.11M)[{"date":"2019-12-31","value":-14644800000,"profit":false},{"date":"2020-12-31","value":-18879000000,"profit":false},{"date":"2021-12-31","value":-17968200000,"profit":false},{"date":"2022-12-31","value":-27816900000,"profit":false},{"date":"2023-12-31","value":-37611000000,"profit":false}]
Income Taxes(21.00K)(19.36M)409.00K313.00K223.00K[{"date":"2019-12-31","value":-5.13,"profit":false},{"date":"2020-12-31","value":-4733.25,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":76.53,"profit":true},{"date":"2023-12-31","value":54.52,"profit":true}]
Income After Taxes(146.43M)(169.43M)(180.09M)(278.48M)(376.33M)[{"date":"2019-12-31","value":-14642700000,"profit":false},{"date":"2020-12-31","value":-16943100000,"profit":false},{"date":"2021-12-31","value":-18009100000,"profit":false},{"date":"2022-12-31","value":-27848200000,"profit":false},{"date":"2023-12-31","value":-37633300000,"profit":false}]
Income From Continuous Operations(146.43M)(169.43M)(180.09M)(278.48M)(376.33M)[{"date":"2019-12-31","value":-14642700000,"profit":false},{"date":"2020-12-31","value":-16943100000,"profit":false},{"date":"2021-12-31","value":-18009100000,"profit":false},{"date":"2022-12-31","value":-27848200000,"profit":false},{"date":"2023-12-31","value":-37633300000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(146.43M)(169.43M)(180.09M)(278.48M)(111.40M)[{"date":"2019-12-31","value":-14642700000,"profit":false},{"date":"2020-12-31","value":-16943100000,"profit":false},{"date":"2021-12-31","value":-18009100000,"profit":false},{"date":"2022-12-31","value":-27848200000,"profit":false},{"date":"2023-12-31","value":-11139900000,"profit":false}]
EPS (Diluted)(2.98)(1.48)(3.03)(4.37)(4.75)[{"date":"2019-12-31","value":-298,"profit":false},{"date":"2020-12-31","value":-148,"profit":false},{"date":"2021-12-31","value":-303,"profit":false},{"date":"2022-12-31","value":-437,"profit":false},{"date":"2023-12-31","value":-475,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

TVTX
Cash Ratio 1.46
Current Ratio 1.71
Quick Ratio 1.68

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

TVTX
ROA (LTM) -26.14%
ROE (LTM) -279.94%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

TVTX
Debt Ratio Lower is generally better. Negative is bad. 1.06
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.06

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

TVTX
Trailing PE NM
Forward PE NM
P/S (TTM) 7.35
P/B 76.10
Price/FCF NM
EV/R 7.96
EV/Ebitda NM

FAQs

What is Travere Therapeutics Inc share price today?

Travere Therapeutics Inc (TVTX) share price today is $17.15

Can Indians buy Travere Therapeutics Inc shares?

Yes, Indians can buy shares of Travere Therapeutics Inc (TVTX) on Vested. To buy Travere Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TVTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Travere Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Travere Therapeutics Inc (TVTX) via the Vested app. You can start investing in Travere Therapeutics Inc (TVTX) with a minimum investment of $1.

How to invest in Travere Therapeutics Inc shares from India?

You can invest in shares of Travere Therapeutics Inc (TVTX) via Vested in three simple steps:

  • Click on Sign Up or Invest in TVTX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Travere Therapeutics Inc shares
What is Travere Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Travere Therapeutics Inc (TVTX) is $20.33. The 52-week low price of Travere Therapeutics Inc (TVTX) is $5.12.

What is Travere Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Travere Therapeutics Inc (TVTX) is

What is Travere Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Travere Therapeutics Inc (TVTX) is 76.10

What is Travere Therapeutics Inc dividend yield?

The dividend yield of Travere Therapeutics Inc (TVTX) is 0.00%

What is the Market Cap of Travere Therapeutics Inc?

The market capitalization of Travere Therapeutics Inc (TVTX) is $1.50B

What is Travere Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Travere Therapeutics Inc is TVTX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top